Long-term outcomes after retinal artery occlusion
Official title: Long-Term Cardiovascular and Cerebrovascular Outcomes After Retinal Artery Occlusion: A Nationwide Study
Run by Chonnam National University Hospital · NCT07482228 · Data updated 2026-11-12
Using Korea's national health records, this study will see if common medicines — antiplatelet agents, blood thinners, or statins — change long-term heart and stroke risks for people newly diagnosed with retinal artery occlusion.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 15000 (estimated) |
| Sponsor | Chonnam National University Hospital Academic / other |
| Locations | 1 site (Gwangju, Gwangju) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | August 31, 2027 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07482228 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People newly diagnosed with retinal artery occlusion in Korea during the 2010–2024 period who do not have a prior RAO diagnosis and do not have giant cell arteritis.
✕Probably not a fit
Patients with RAO diagnosed before 2010, those with giant cell arteritis, or people outside the Korean National Health Insurance system are unlikely to be represented and may not benefit directly from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This nationwide, population-based analysis will identify patients newly diagnosed with central or branch retinal artery occlusion in the Korean National Health Insurance Service database from 2010 through 2024. It will compare long-term cardiovascular and cerebrovascular outcomes such as ischemic stroke and myocardial infarction across treatment groups using prescriptions for antiplatelet agents, anticoagulants, and statins and adjust for comorbidities and demographic factors. The observational design will use administrative claims and diagnostic codes to capture events and treatment exposure with statistical methods to address confounding. Results aim to clarify the epidemiology of RAO and whether specific medical therapies are associated with improved long-term outcomes.
Why it matters
Potential benefit: If successful, the results could help doctors choose medicines that reduce the risk of stroke and heart attack after retinal artery occlusion.
How similar studies have gone: Previous observational studies have linked RAO to higher risks of ischemic stroke and cardiovascular events, but large nationwide analyses examining the effects of antiplatelet, anticoagulant, or statin use on long-term outcomes are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly diagnosed with retinal artery occlusion Exclusion Criteria: * Patients with a prior diagnosis of retinal artery occlusion before the study period. * Patients diagnosed with giant cell arteritis.
Where it's running
-
Chonnam National University Hospital
Gwangju, Gwangju, South Korea Recruiting
Study contacts
- Principal investigator: Seung Hun Lee, MD, PhD — Chonnam National University Hospital
- Study coordinator: Seung Hun Lee, MD, PhD
- Email: lsh8602@naver.com
- Phone: 82-62-220-6246
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Is routine follow-up paracentesis needed after starting antibiotics for SBP in cirrhosis?
We’re testing whether doing a follow-up paracentesis at 48 hours after starting antibiotics changes outcomes for people with spontaneous bacterial peritonitis due to liver cirrhosis.
-
Optimal timing of staged complete revascularization in STEMI with multivessel disease
This trial tests whether performing staged complete revascularization during the hospital stay or after discharge is best for STEMI patients with multivessel disease.
-
Abbreviated antithrombotic therapy after PCI in AF and MI
This trial tests whether DOAC-only therapy works as well as DOAC plus clopidogrel after PCI in people with atrial fibrillation and a recent heart attack.
-
Norepinephrine vs Dopamine as the First Vasoactive Drug in Cardiogenic Shock
This trial tests whether norepinephrine or dopamine works better and is safer as the first drug given to adults with cardiogenic shock.
-
When to do coronary angiography for NSTEMI with acute heart failure
This trial will test whether doing coronary angiography immediately (within 2 hours) versus delaying it after stabilization reduces deaths, heart attacks, or heart-failure hospitalizations over 12 months in adults with NSTEMI complicated by acute decompensated heart failure.
-
Comparing drug-coated balloon angioplasty versus drug-eluting stents for new coronary artery blockages
This study will test whether drug-coated balloon angioplasty works as well as drug-eluting stents for adults with new coronary artery narrowings in vessels at least 3.0 mm wide.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.